图书简介

1. History, diagnosis, and epidemiology; 1 David L. Scott: The history of rheumatoid arthritis; 2 Daniel Aletaha and Helga Radner: Diagnosis; 3 James Gwinnutt and Deborah Symmons: The descriptive epidemiology of rheumatoid arthritis; 4 Lars Klareskog and Lars Alfredsson: Modifiable and other risk factors for rheumatoid arthritis: a basis for prevention and better therapy; 2. Pathogenesis; 5 Anne Barton: Genetics and epigenetics of rheumatoid arthritis; 6 Thomas Crowley, Jason Turner, Andrew Filer, Andy Clark, and Chris Buckley: Dysregulation of synovial fibroblasts in rheumatoid arthritis; 7 Tom W. J. Huizinga: Autoantibodies in rheumatoid arthritis; 8 Soi-Cheng Law, Pascale Wehr, Harriet Purvis, and Ranjeny Thomas: Dendritic cells and T cells in rheumatoid arthritis; 9 Ukrike Steffen and Georg Schett: Mechanisms of bone and cartilage destruction; 10 Marina Frleta-Gilchrist and Iain B. McInnes: Cytokines and other mediators; 3. Clinical presentation; 11 Annette van der Helm-van Mil: Clinical features of rheumatoid arthritis; 12 Karim Raza, Catherine McGrath, Laurette van Boheemen, and Dirkjan van Schaardenburg: Pre-rheumatoid arthritis; 13 Katherine MacDonald, Jennifer Hannah, and James Galloway: Non-articular manifestations of rheumatoid arthritis; 14 Kimme Hyrich and Sarah Skeoch: Comorbidity in rheumatoid arthritis; 4. Disease assessment; 15 Josef Smolen: Disease activity assessment in rheumatoid arthritis; 16 Douglas Veale and Ursula Fearon: Synovial biopsies; 17 Charles Peterfy, Philip Conaghan, and Mikkel Ostergaard: Radiography in rheumatoid arthritis; 18 Andrew Filer, Maria Antonietta D’Agostino, and Ilfita Sahbudin: Ultrasound in rheumatoid arthritis; 19 Charles Peterfy, Philip Conaghan, and Mikkel Ostergaard: MRI in rheumatoid arthritis; 5. Impact on life; 20 Kathryn A. Gibson and Theodore Pincus: Patient physical function in rheumatoid arthritis; 21 Emma Dures and Neil Basu: Fatigue; 22 David L. Scott and Allan Wailoo: Health economics; 23 Suzanne Verstappen, Cheryl Jones, Abdullah Houssien, and James Galloway: Rheumatoid arthritis and work; 6. Non-drug treatments; 24 Lindsay Bearne and Christina Opava: Exercise; 25 Heidi Siddle and Anthony Redmond: Foot health; 26 Alison Hammond, Joanne Adams, and Yeliz Prior: Occupational therapy; 27 Marieke M.J.H. Voshaar: Self-management: a patient’s perspective; 7. Drug treatments; 28 Mark D Russell and Nidhi Sofat: Analgesics, Opioids, and NSAIDs; 29 Johannes W. G. Jacobs, Marlies C. van der Goes, Johannes W. J. Bijlsma, and Jose A. P. da Silva: Glucocorticoids; 30 David L. Scott: Conventional disease modifying drugs; 31 Peter Taylor and Nehal Narayan: Tumour necrosis factor inhibitors; 32 Neelam Hassan and Ernest Choy: Interleukin-6 inhibitors; 33 Yuzaiful Yusof, Edward Vital, and Maya Buch: B-cell therapies; 34 Vibeke Strand, Jeffrey Kaine, and John Isaacs: Biosimilars; 35 Meghna Jani, John Isaacs, and Vibeke Strand: Immunogenicity in response to biologic agents; 36 Katie Bechman, James Galloway, and Peter Taylor: The use of JAK inhibitors in the treatment of rheumatoid arthritis; 37 Ben G.T. Coumbe, Elena Nikiphorou, and Tuulikki Sokka-Isler: Combination therapy in rheumatoid arthritis; 38 Jeremy Sokolove: Translation of new therapies: from bench to bedside; 39 James Galloway and Mark Yates: Adverse events in clinical studies in rheumatoid arthritis; 8. Management and outcomes; 40 Tom W. J. Huizinga, Annette van der Helm-van Mil, and Andrew Cope: Prevention of rheumatoid arthritis; 41 Kenneth F Baker and Arthur G Pratt: Treatment targets and remission; 42 David L. Scott: Clinical outcomes; 43 Anna-Birgitte Aga, Espen A. Haavardsholm, Till Uhlig, and Tore K. Kvien: Clinical guidelines; 44 Angela Zink and Anja Strangfeld: European biologics registers; 45 Jeff Greenberg and Sheetal Patel: Voluntary patient registries

Trade Policy 买家须知